TR200202253T2 - IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri - Google Patents

IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri

Info

Publication number
TR200202253T2
TR200202253T2 TR2002/02253T TR200202253T TR200202253T2 TR 200202253 T2 TR200202253 T2 TR 200202253T2 TR 2002/02253 T TR2002/02253 T TR 2002/02253T TR 200202253 T TR200202253 T TR 200202253T TR 200202253 T2 TR200202253 T2 TR 200202253T2
Authority
TR
Turkey
Prior art keywords
treatment
recombinant
antagonists useful
induced disorders
mabs
Prior art date
Application number
TR2002/02253T
Other languages
English (en)
Inventor
D. Holmes Stephen
Sen Ho Yen
Harrison Taylor Alexander
S. Abdel-Meguid Sherin
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc filed Critical Smithkline Beecham Corporation
Publication of TR200202253T2 publication Critical patent/TR200202253T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Kimerik, hümanize ve diger IL-18 mAb' ler yüksek afiniteli nötrleyici mAb' lerden türetilmis olup, bunlari içeren farmasötik terkipler, tedavi ve teshis yöntemleri saglanmaktadir.
TR2002/02253T 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri TR200202253T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
TR200202253T2 true TR200202253T2 (tr) 2002-12-23

Family

ID=22419067

Family Applications (3)

Application Number Title Priority Date Filing Date
TR2001/02733T TR200102733T2 (tr) 1999-03-19 2000-03-17 IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
TR2002/02254T TR200202254T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
TR2002/02253T TR200202253T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2001/02733T TR200102733T2 (tr) 1999-03-19 2000-03-17 IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
TR2002/02254T TR200202254T2 (tr) 1999-03-19 2000-03-17 IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.

Country Status (28)

Country Link
US (2) US6706487B1 (tr)
EP (2) EP1961768A1 (tr)
JP (1) JP2002542769A (tr)
KR (1) KR100697120B1 (tr)
CN (1) CN1246335C (tr)
AR (1) AR022952A1 (tr)
AT (1) ATE402191T1 (tr)
AU (1) AU764622B2 (tr)
BR (1) BR0008688A (tr)
CA (1) CA2368965C (tr)
CO (1) CO5470287A1 (tr)
CY (1) CY1108387T1 (tr)
CZ (1) CZ303704B6 (tr)
DE (1) DE60039589D1 (tr)
DK (1) DK1163271T3 (tr)
ES (1) ES2308974T3 (tr)
HK (1) HK1043798B (tr)
HU (1) HU228931B1 (tr)
IL (1) IL144995A0 (tr)
MY (1) MY124219A (tr)
NO (1) NO330391B1 (tr)
NZ (1) NZ513699A (tr)
PL (1) PL202396B1 (tr)
PT (1) PT1163271E (tr)
SI (1) SI1163271T1 (tr)
TR (3) TR200102733T2 (tr)
WO (1) WO2000056771A1 (tr)
ZA (1) ZA200107639B (tr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ES2349348T3 (es) * 2000-01-27 2010-12-30 Medimmune, Llc Anticuerpos neutralizantes de rsv de ultra alta afinidad.
TW201305214A (zh) * 2000-02-10 2013-02-01 Abbott Gmbh & Co Kg 與人類間白素－１８結合之抗體，及其製法及用途
KR20020086540A (ko) * 2000-02-21 2002-11-18 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
MY157173A (en) * 2006-05-25 2016-05-13 Glaxo Group Ltd Modified humanised anti-interleukin-18
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
CN102936287B (zh) * 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
JP2012500242A (ja) * 2008-08-18 2012-01-05 グラクソ グループ リミテッド Ｉｌ−１８アンタゴニストを用いる自己免疫疾患の治療
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
EP2377583A1 (en) * 2009-06-30 2011-10-19 Gosen Co., Ltd. Racket string, method for manufacturing same, and racket strung with same
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011098424A2 (en) * 2010-02-09 2011-08-18 Glaxo Group Limited Treatment of a metabolic disorder
EP2538965B1 (en) * 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
US20130109107A1 (en) * 2010-05-25 2013-05-02 The Regents Of The University Of Colorado Diagnosis and treatment of autoimmune disease
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
MX2013007067A (es) 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10570199B2 (en) 2012-11-21 2020-02-25 Km Biologics Co., Ltd. Human antibody against IL-18
SG11201706879UA (en) * 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
JP2023530489A (ja) * 2020-06-18 2023-07-18 ネクストキュア インコーポレイテッド Ｆｌｒｔ３媒介性シグナル伝達を調節するための組成物及び方法
EP4371573A1 (en) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medicinal composition for treating inflammatory bowel disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ES2145004T3 (es) 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
NO20014524D0 (no) 2001-09-18
EP1163271A4 (en) 2003-04-09
ZA200107639B (en) 2002-09-17
AU3901600A (en) 2000-10-09
IL144995A0 (en) 2002-06-30
DE60039589D1 (de) 2008-09-04
HUP0200502A3 (en) 2003-12-29
CY1108387T1 (el) 2014-02-12
CN1246335C (zh) 2006-03-22
JP2002542769A (ja) 2002-12-17
CZ303704B6 (cs) 2013-03-27
NO330391B1 (no) 2011-04-04
PL202396B1 (pl) 2009-06-30
AR022952A1 (es) 2002-09-04
CA2368965A1 (en) 2000-09-28
CZ20013362A3 (cs) 2002-03-13
WO2000056771A1 (en) 2000-09-28
KR100697120B1 (ko) 2007-03-20
NZ513699A (en) 2004-02-27
CN1352650A (zh) 2002-06-05
CA2368965C (en) 2010-05-18
NO20014524L (no) 2001-11-14
ES2308974T3 (es) 2008-12-16
TR200202254T2 (tr) 2002-12-23
CO5470287A1 (es) 2004-12-30
DK1163271T3 (da) 2008-11-10
TR200102733T2 (tr) 2002-04-22
US20040141964A1 (en) 2004-07-22
HU228931B1 (en) 2013-06-28
AU764622B2 (en) 2003-08-28
PL350460A1 (en) 2002-12-16
KR20020008130A (ko) 2002-01-29
SI1163271T1 (sl) 2008-10-31
EP1961768A1 (en) 2008-08-27
PT1163271E (pt) 2008-09-16
US6706487B1 (en) 2004-03-16
MY124219A (en) 2006-06-30
HUP0200502A2 (en) 2002-06-29
ATE402191T1 (de) 2008-08-15
BR0008688A (pt) 2002-01-08
HK1043798B (zh) 2009-04-09
HK1043798A1 (en) 2002-09-27
EP1163271A1 (en) 2001-12-19
EP1163271B1 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
LTPA2020001I1 (lt) Anti-IL-12 antikūnai, kompozicijos, būdai ir panaudojimas Krono patologijai gydyti
EP1470146B8 (en) Antibodies against the muc18 antigen
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
RS80704A (en) ANTI- av?6.ANTIBODIES
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
WO2004031105A3 (en) Use of a33 antigens and jam-it
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
DE59911103D1 (de) ISOLIERTE UND GEREINIGTE HUMANE LÖSLICHE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGC ALPHA1/BETA1)
WO2002092625A3 (en) Moraxella(branhamella) catarrhalis antigens